3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
16
Thoracic
12
Gynecologic
11
Genitourinary
11
Other solid neoplasm
9
Head & Neck
7
Breast
5
Dermatologic
3
Endocrine
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
NET
1
Lymphoid
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
lutetium Lu 177 dotatate
41
Everolimus
38
Magnetic Resonance Spectroscopy
18
Temozolomide
17
lanreotide
16
gallium Ga 68 dotatate
15
Octreotide
14
pembrolizumab
13
Nivolumab
13
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
surufatinib
9
pasireotide
9
Sunitinib
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Lutetium-177
8
Carboplatin
8
amino-acid, glucose, and electrolyte solution
6
Ipilimumab
6
Ga(III)-DOTATOC
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
copper dotatate CU-64
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
zimberelimab
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled